|
[1]
|
(2024) Global Hepatitis Report 2024: Action for Access in Low-and Middle-Income Countries. World Health Organization.
|
|
[2]
|
Razavi-Shearer, D., Gamkrelidze, I., Pan, C., et al. (2023) Global Prevalence, Cascade of Care, and Prophylaxis Coverage of Hepatitis B in 2022: A Modelling Study. The Lancet Gastroenterology & Hepatology, 8, 879-907.
|
|
[3]
|
艾滋病毒、病毒性肝炎和性传播感染2022-2030年全球卫生部门战略[EB/OL].
https://www.who.int/zh/publications/i/item/9789240053779, 2025-04-02.
|
|
[4]
|
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版) [J]. 中华肝脏病杂志, 2022, 30(12): 1309-1331.
|
|
[5]
|
Xie, D., Ren, Z., Zhou, J., Fan, J. and Gao, Q. (2020) 2019 Chinese Clinical Guidelines for the Management of Hepatocellular Carcinoma: Updates and Insights. Hepatobiliary Surgery and Nutrition, 9, 452-463. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Xia, Y. and Guo, H. (2020) Hepatitis B Virus cccDNA: Formation, Regulation and Therapeutic Potential. Antiviral Research, 180, Article ID: 104824. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Kramvis, A., Chang, K., Dandri, M., Farci, P., Glebe, D., Hu, J., et al. (2022) A Roadmap for Serum Biomarkers for Hepatitis B Virus: Current Status and Future Outlook. Nature Reviews Gastroenterology & Hepatology, 19, 727-745. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., et al. (2012) Sodium Taurocholate Cotransporting Polypeptide Is a Functional Receptor for Human Hepatitis B and D Virus. eLife, 1, e00049. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Trépo, C., Chan, H.L.Y. and Lok, A. (2014) Hepatitis B Virus Infection. The Lancet, 384, 2053-2063. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Gish, R., Jia, J., Locarnini, S. and Zoulim, F. (2012) Selection of Chronic Hepatitis B Therapy with High Barrier to Resistance. The Lancet Infectious Diseases, 12, 341-353. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Rivkin, A. (2005) A Review of Entecavir in the Treatment of Chronic Hepatitis B Infection. Current Medical Research and Opinion, 21, 1845-1856. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Zoulim, F. (2011) Hepatitis B Virus Resistance to Antiviral Drugs: Where Are We Going? Liver International, 31, 111-116. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Buti, M., Marcos‐Fosch, C. and Esteban, R. (2021) Nucleos(t)ide Analogue Therapy: The Role of Tenofovir Alafenamide. Liver International, 41, 9-14. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Kim, J.H. (2014) Molecular Diagnosis and Treatment of Drug-Resistant Hepatitis B Virus. World Journal of Gastroenterology, 20, 5708-5720. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kwon, H. and Lok, A.S. (2011) Hepatitis B Therapy. Nature Reviews Gastroenterology & Hepatology, 8, 275-284. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Chon, H.Y., Ahn, S.H., Kim, Y.J., Yoon, J., Lee, J., Sinn, D.H., et al. (2021) Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Treatment-Naive Hepatitis B Patients. Hepatology International, 15, 1328-1336. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Choi, J., Choi, W. and Lim, Y. (2023) Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs? Clinics in Liver Disease, 27, 809-818. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Park, C.H., Jung, S.W., Shin, J.W., Bae, M.A., Lee, Y.I., Park, Y.T., et al. (2016) Comparison of Tenofovir Plus Lamivudine versus Tenofovir Monotherapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. Clinical and Molecular Hepatology, 22, 152-159. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Woo, H.Y., Park, J.Y., Bae, S.H., Kim, C.W., Jang, J.Y., Tak, W.Y., et al. (2020) Entecavir + Tenofovir vs. Lamivudine/Telbivudine + Adefovir in Chronic Hepatitis B Patients with Prior Suboptimal Response. Clinical and Molecular Hepatology, 26, 352-363. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Yip, T.C., Lai, J.C., Yam, T., Tse, Y., Hui, V.W., Lai, M.S., et al. (2024) Long-Term Use of Tenofovir Disoproxil Fumarate Increases Fracture Risk in Elderly Patients with Chronic Hepatitis B. Journal of Hepatology, 80, 553-563. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Lai, C.L., et al. (2007) Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. The New England Journal of Medicine, 357, 2576-2588.
|
|
[22]
|
Buti, M. and Esteban, R. (2003) Adefovir Dipivoxil. Drugs Today (Barc), 39, 127-135.
|
|
[23]
|
Choi, J. (2023) Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs? Clinical Liver Disease, 27, 809-818.
|
|
[24]
|
Rehermann, B. and Nascimbeni, M. (2005) Immunology of Hepatitis B Virus and Hepatitis C Virus Infection. Nature Reviews Immunology, 5, 215-229. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Lau, G.K.K., Piratvisuth, T., Luo, K.X., Marcellin, P., Thongsawat, S., Cooksley, G., et al. (2005) Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine, 352, 2682-2695. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Terrault, N.A., Bzowej, N.H., Chang, K., Hwang, J.P., Jonas, M.M. and Murad, M.H. (2015) AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology, 63, 261-283. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Jonas, M.M., Chang, M., Sokal, E., Schwarz, K.B., Kelly, D., Kim, K.M., et al. (2015) Randomized, Controlled Trial of Entecavir versus Placebo in Children with Hepatitis B Envelope Antigen-Positive Chronic Hepatitis B. Hepatology, 63, 377-387. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Chan, H.L.Y., Fung, S., Seto, W.K., Chuang, W., Chen, C., Kim, H.J., et al. (2016) Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for the Treatment of HBeAg-Positive Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial. The Lancet Gastroenterology & Hepatology, 1, 185-195. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Papatheodoridis, G.V., Mimidis, K., Manolakopoulos, S., Gatselis, N., Goulis, J., Kapatais, A., et al. (2022) HERACLIS‐TAF: A Multi‐Centre Prospective Cohort Study on 2‐Year Safety and Efficacy of Tenofovir Alafenamide in Patients with Chronic Hepatitis B with Renal and/or Bone Disorders or Risks. Alimentary Pharmacology & Therapeutics, 56, 702-712. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Janssen, H.L.A., Lim, Y., Lampertico, P., Heo, J., Chen, C., Fournier, C., et al. (2024) Switching to Tenofovir Alafenamide in Patients with Virologically Suppressed Chronic Hepatitis B and Renal or Hepatic Impairment: Final Week 96 Results from an Open-Label, Multicentre, Phase 2 Study. The Lancet Gastroenterology & Hepatology, 9, 718-733. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Lok, A.S.F., McMahon, B.J., Brown, R.S., Wong, J.B., Ahmed, A.T., Farah, W., et al. (2015) Antiviral Therapy for Chronic Hepatitis B Viral Infection in Adults: A Systematic Review and Meta‐analysis. Hepatology, 63, 284-306. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Funk, A.L. (2021) Efficacy and Safety of Antiviral Prophylaxis during Pregnancy to Prevent Mother-to-Child Transmission of Hepatitis B Virus: A Systematic Review and Meta-Analysis. The Lancet Infectious Diseases, 21, 70-84.
|
|
[33]
|
Pan, C.Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., et al. (2016) Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. New England Journal of Medicine, 374, 2324-2334. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Benhamou, Y. (2005) HIV-1/hepatitis B Coinfection. Expert Review of Anti-infective Therapy, 3, 229-239. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Mak, J.W.Y., Law, A.W.H., Law, K.W.T., Ho, R., Cheung, C.K.M. and Law, M.F. (2023) Prevention and Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies in the Targeted Therapy Era. World Journal of Gastroenterology, 29, 4942-4961. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Zoulim, F., Lenz, O., Vandenbossche, J.J., Talloen, W., Verbinnen, T., Moscalu, I., et al. (2020) JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection. Gastroenterology, 159, 521-533.e9. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Janssen, H.L.A., Hou, J., Asselah, T., Chan, H.L.Y., Zoulim, F., Tanaka, Y., et al. (2023) Randomised Phase 2 Study (JADE) of the HBV Capsid Assembly Modulator JNJ-56136379 with or without a Nucleos(t)ide Analogue in Patients with Chronic Hepatitis B Infection. Gut, 72, 1385-1398. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Vendeville, S., Amblard, F., Bassit, L., Beigelman, L.N., Blatt, L.M., Chen, X., et al. (2024) The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator Alg-001075. Journal of Medicinal Chemistry, 67, 21126-21142. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Yuen, M., Lim, S., Plesniak, R., Tsuji, K., Janssen, H.L.A., Pojoga, C., et al. (2022) Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. New England Journal of Medicine, 387, 1957-1968. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Yuen, M., Heo, J., Jang, J., Yoon, J., Kweon, Y., Park, S., et al. (2021) Safety, Tolerability and Antiviral Activity of the Antisense Oligonucleotide Bepirovirsen in Patients with Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial. Nature Medicine, 27, 1725-1734. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Gane, E., Lim, Y., Kim, J.B., Jadhav, V., Shen, L., Bakardjiev, A.I., et al. (2023) Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results from Randomized Clinical Trials. Journal of Hepatology, 79, 924-932. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Zhaori, G. (2018) Potential Clinical Application of RNAi‐Based Therapeutic Strategies for Treatment of Chronic Hepatitis B. Pediatric Investigation, 2, 4-7. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Zhao, H., Shao, X., Yu, Y., Huang, L., Amor, N.P., Guo, K., et al. (2024) A Therapeutic Hepatitis B mRNA Vaccine with Strong Immunogenicity and Persistent Virological Suppression. npj Vaccines, 9, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Nguyen, M.H., Wong, G., Gane, E., Kao, J. and Dusheiko, G. (2020) Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clinical Microbiology Reviews, 33, e00046-19. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Du, Y., Wu, J., Liu, J., Zheng, X., Yang, D. and Lu, M. (2022) Toll-Like Receptor-Mediated Innate Immunity Orchestrates Adaptive Immune Responses in HBV Infection. Frontiers in Immunology, 13, Article 965018. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Janssen, H.L.A., Brunetto, M.R., Kim, Y.J., Ferrari, C., Massetto, B., Nguyen, A., et al. (2018) Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally Suppressed Patients with Chronic Hepatitis B. Journal of Hepatology, 68, 431-440. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Fung, S., Choi, H.S.J., Gehring, A. and Janssen, H.L.A. (2022) Getting to HBV Cure: The Promising Paths Forward. Hepatology, 76, 233-250. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Lee, H.W., Park, J.Y., Hong, T., Park, M.S. and Ahn, S.H. (2020) Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 18, 3043-3045.e1. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Lempp, F.A., Volz, T., Cameroni, E., Benigni, F., Zhou, J., Rosen, L.E., et al. (2023) Potent Broadly Neutralizing Antibody VIR-3434 Controls Hepatitis B and D Virus Infection and Reduces HBsAg in Humanized Mice. Journal of Hepatology, 79, 1129-1138. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Li, S., Li, N., Yang, S., Deng, H., Li, Y., Wang, Y., et al. (2022) The Study of Immune Checkpoint Inhibitors in Chronic Hepatitis B Virus Infection. International Immunopharmacology, 109, Article ID: 108842. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Urbanek-Quaing, M., Chou, Y., Gupta, M.K., Steppich, K., Bremer, B., Schmaus, H., et al. (2024) Enhancing HBV-Specific T Cell Responses through a Combination of Epigenetic Modulation and Immune Checkpoint Inhibition. Hepatology. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Xie, Y., Zhu, H., Guo, Y., Ma, Z., Qi, X., Yang, F., et al. (2022) Reduction of Hepatitis B Surface Antigen May Be More Significant in Pegylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study. Canadian Journal of Gastroenterology and Hepatology, 2022, Article ID: 4325352. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Ma, H., Lim, T.H., Leerapun, A., Weltman, M., Jia, J., Lim, Y., et al. (2021) Therapeutic Vaccine BRII-179 Restores HBV-Specific Immune Responses in Patients with Chronic HBV in a Phase IB/IIA Study. JHEP Reports, 3, Article ID: 100361. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Yuen, M., Lim, Y., Yoon, K.T., Lim, T., Heo, J., Tangkijvanich, P., et al. (2024) VIR-2218 (Elebsiran) Plus Pegylated Interferon-Alfa-2a in Participants with Chronic Hepatitis B Virus Infection: A Phase 2 Study. The Lancet Gastroenterology & Hepatology, 9, 1121-1132. [Google Scholar] [CrossRef] [PubMed]
|